Untangling PINK1–Tau Crosstalk and Co-Morbidity Mechanisms in Parkinson’s Disease

Study Rationale:                         

Parkinson’s disease is a brain disorder that gets worse over time, causing problems with movement and cognitive abilities. Two key problems are often seen together in this disease: damage to the cell’s energy and metabolic hubs (mitochondria) and the buildup of harmful proteins. For many years, researchers focused on a protein called alpha-synuclein as the main culprit. Recently, however, growing evidence shows that another protein, called tau, also plays an important role in Parkinson’s. A protein named PINK1 normally helps cells clear out damaged mitochondria, but when PINK1 does not work properly, tau becomes more harmful. In turn, tau blocks PINK1’s protective role, creating a harmful cycle that may drive early brain damage.

Hypothesis:

PINK1 and tau trap brain cells in a harmful cycle. When PINK1 fails, tau becomes more damaging. As tau builds up, it further weakens PINK1’s defenses. This cycle may start early brain damage in Parkinson’s disease and stopping it could help protect cells.

Study Design:

Advanced tools in mice and human brain cell models will be used to test how problems with PINK1 lead to harmful changes in tau and how tau disrupts mitochondria. A special preclinical model designed to keep PINK1 “switched on” will be applied to measure when and where cells fail to remove damaged mitochondria, how tau spreads, and which brain regions are most at risk. Early warning signs-molecular “flags” such as pS65-Ub and tau changes-will also be studied as possible predictors of when Parkinson’s begins. Through these approaches, weak points in the disease process where treatment may work best will be identified.

Impact on Diagnosis/Treatment of Parkinson’s disease:                    

If the harmful cycle between PINK1 and tau is confirmed, new ways to diagnose Parkinson’s earlier and test treatments aimed at boosting PINK1’s activity may be created. By strengthening PINK1’s function, brain cells may be protected, and disease progression may be slowed.

Next Steps for Development:

Next steps will include testing drugs or gene therapies aimed at enhancing PINK1’s function. In addition, signals related to PINK1 and tau in blood or spinal fluid will be explored as possible early markers, so that diagnosis may be improved and treatment may be started sooner.